skip to Main Content

Dr. Oberstein on PEGPH20 in Patients With Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Paul E. Oberstein, MD, assistant professor of medicine, assistant director, Pancreatic Cancer Center, director, Gastrointestinal Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of pegylated hyaluronidase (PEGPH20) in advanced pancreatic cancer.

PEGPH20, is an investigational agent and potential therapy for patients with advanced pancreatic cancer, says Oberstein. Watch the video . . .

Back To Top